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ABSTRACT
Background The UK Lung Cancer Screening (UKLS)
trial is a randomised pilot trial of low-dose CT (LDCT)
screening for individuals at high risk of lung cancer. We
assessed the long-term psychosocial impact on
individuals participating in the UKLS trial.
Methods A random sample of individuals aged
50–75 years was contacted via primary care. High-risk
individuals who completed T0 questionnaires (baseline)
were randomised to LDCT screening (intervention) or
usual care (no screening control). T1 questionnaires were
sent 2 weeks after baseline scan results or control
assignment. T2 questionnaires were sent up to 2 years
after recruitment. Measures included cancer distress,
anxiety, depression and decision satisfaction.
Results A total of 4037 high-risk individuals were
randomised and they completed T0 questionnaires
(n=2018 intervention, n=2019 control). Cancer distress
was higher at T1 in intervention arm participants who
received positive screening results (p≤0.001), but not at
T2 (p=0.04). T2 anxiety (p≤0.001) and depression
(p≤0.01) were higher in the control arm, but the
absolute differences were small and not clinically
relevant. At both time points, fewer control than
screened participants were satisﬁed with their decision
to participate in UKLS (p≤0.001). Regardless of trial
allocation, cancer distress was higher in women
(p≤0.01), participants aged ≤65 years (p≤0.001),
current smokers (p≤0.001), those with lung cancer
experience (p≤0.001) and those recruited from the
Liverpool area (p≤0.001).
Conclusion Lung cancer screening using LDCT appears
to have no clinically signiﬁcant long-term psychosocial
impact on high-risk participants. Strategies for engaging
and supporting underserved groups are the key to
implement routine lung cancer screening in the UK.
Trial registration number ISRCTN 78513845;
results.
INTRODUCTION
Lung cancer is the leading cause of cancer-related
mortality in the UK.1 Although improving, the
5-year survival rate for lung cancer in the UK is
approximately 10% and lower than in other coun-
tries with comparable healthcare systems.2 This is
partly due to patients presenting at an advanced
disease stage, with over 65% of cases diagnosed at
stage III or stage IV3 when treatment is usually
palliative.
Effective early detection strategies are critical for
enabling earlier diagnosis, curative treatment and
better lung cancer prognosis. Lung cancer screening
using low-dose CT (LDCT) in high-risk groups has
demonstrated a 20% relative reduction in lung
cancer mortality compared with chest X-ray in the
US National Lung Screening Trial (NLST).4
However, false-positive rates of 20%–50% have
been reported.4 5 Policy decisions about whether to
implement a new screening technology require evi-
dence regarding psychosocial consequences that
may inﬂuence successful application in routine
practice.
Previous controlled trials have reported the psy-
chosocial effects of LDCT lung cancer screening.
The Danish Lung Cancer Screening Trial
(DLCST)6 7 and Dutch-Belgian NELSON trial8
found no differential effect of trial allocation on a
range of psychosocial outcomes at 1 and 2 years
follow-up, respectively. Temporary adverse effects
of receiving abnormal results have been observed in
high-risk participants randomised to LDCT screen-
ing.9–11 The NELSON trial reported poorer quality
of life and increased anxiety and cancer distress at
Key messages
What is the key question?
▸ What is the long-term psychosocial impact on
high-risk individuals taking part in a UK
randomised pilot trial of low-dose CT lung
screening?
What is the bottom line?
▸ Low-dose CT screening appears to have no
clinically signiﬁcant psychosocial impact on
high-risk participants in the long term, but
subgroups including women, younger
participants, smokers, those with experience of
lung cancer and those living in deprived areas
may require targeted information and support.
Why read on?
▸ The evidence will contribute to clinical and
policy decisions regarding the successful and
equitable implementation of low-dose CT lung
screening for high-risk individuals in the UK.
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2 months follow-up in recipients of an indeterminate scan
result.11 However, these effects had diminished at 6 months
follow-up.8 Recently, the NLST reported no signiﬁcant differ-
ences between those receiving an abnormal and those receiving
normal lung screening result in anxiety and health-related
quality of life at 1 and 6 months follow-up.12
The UK Lung Cancer Screening (UKLS) pilot trial is the ﬁrst to
assess the feasibility, cost-effectiveness and psychosocial impact
of lung cancer screening using a single LDCT screen versus no
screening in a UK high-risk population.13 When considering the
impact of lung cancer screening, it is important to understand
the moderating role of participant characteristics that could
present barriers to successful implementation. For
example, smokers may perceive few beneﬁts of screening14 15
and harbour fatalistic and avoidant beliefs about lung cancer16–18
compared with former or non-smokers. Individuals from
poorer backgrounds may be less enthusiastic about screening and
face more barriers than those from afﬂuent backgrounds.19 In
earlier UKLS reports, trial participation was less likely in
smokers, women, older age groups, those with higher levels of
concern about lung cancer and those in lower socioeconomic
groups.20 21
We report the effects of UKLS trial participation on short-
term and long-term psychosocial outcomes. The primary
hypothesis was that intervention arm participants—in particular
those with a positive (ie, abnormal) baseline scan result—would
report higher short-term cancer distress compared with those in
the control arm, but there would be no differential effects of
trial arm or screening outcome on long-term distress. In second-
ary analyses of outcomes adjusted for a range of covariates, it
was anticipated that subgroups including smokers and those
from socioeconomically deprived areas would report adverse
long-term outcomes regardless of trial allocation or result.
METHODS
Participants and procedures
A random sample of 247 354 individuals aged 50–75 years res-
iding in six recruitment centres at two sites (Liverpool,
Knowsley and Sefton; Cambridgeshire, Peterborough and
Bedfordshire) was sent trial information packs that included a
questionnaire regarding lung cancer risk factors. From the ques-
tionnaire responders, 8729 patients were identiﬁed as having
high risk of lung cancer (≥5% over 5 years) using the LLPv2 risk
prediction model.13 Characteristics of trial non-participants are
reported elsewhere.20 21
Following completion of a further questionnaire to identify
trial eligibility, those meeting the criteria were invited to attend
their local recruitment centre in the Liverpool or Cambridge
area. High-risk individuals who gave informed written consent
were randomly allocated by simple computer pseudo-random
number generation to the intervention (LDCT) or control arms
in a 1:1 ratio.13
Participants completed a touchscreen questionnaire that
included baseline psychosocial measures (T0). A second psycho-
social questionnaire (T1) was sent approximately 2 weeks after
receiving either a letter of assignment to the control group or a
baseline CT scan result letter (intervention arm). T2 psychosocial
questionnaires were sent in a single mailshot during January
2014.
Measures
Primary outcome: lung cancer distress was measured using the
six-item Cancer Worry Scale22 23 anchored to thoughts and feel-
ings about lung cancer during the past week. The scale had
good internal consistency (α>0.81). Total score range was 6–24,
with a score above 12.5 corresponding to a clinically signiﬁcant
threshold score on the General Health Questionnaire-28.24
Secondary outcomes: anxiety and depression were measured
using the Hospital Anxiety and Depression Scale.25 Anxiety and
depression subscales include seven items on a 0–3 scale,
anchored to how participants felt in the last week (score range
0–21) and with good internal consistency (α>0.73). Scores of
0–7 are classiﬁed as ‘normal’, 8–10 as ‘mild’ anxiety or depres-
sion and 11–14 and 15–21 as ‘moderate’ and ‘severe’, respect-
ively.25 Decision satisfaction was assessed with the six-item
Satisfaction with Decision Scale.26 Scores were calculated and
averaged so that possible scores ranged from 1 to 5 (α>0.94).
Due to bi-modal distribution in the present study, a binary vari-
able was created to reﬂect lower decision satisfaction (score <5,
‘not very satisﬁed’) and higher decision satisfaction (score=5,
‘very satisﬁed’).
Demographic variables: age and gender were obtained from
medical records. Participants were identiﬁed as current,
ex-smokers or never-smokers using self-reported smoking status
included in the UKLS risk questionnaire. Socioeconomic depriv-
ation was measured using Index of Multiple Deprivation (IMD)
scores calculated from postcodes and ranked into standard
deprivation quintiles (quintile 1=most deprived, quintile
5=least deprived). Educational attainment, marital group, ethni-
city and experience of lung cancer (self and/or close others)
were included in the T0 questionnaire.
Screening results
As shown in ﬁgure 1, at T1, we categorised baseline CT scan
results into those that required a repeat scan in 3 or 12 months
(positive for repeat scan) or referral to the multidisciplinary
team (MDT) due to a major lung abnormality (positive for
MDT referral), normal (negative) and signiﬁcant incidental ﬁnd-
ings such as aortic aneurisms and pneumonia but with no ﬁnd-
ings suspicious for lung cancer (incidental ﬁnding). Categorising
baseline CT scan results as ‘positive for repeat scan’ at T1
Figure 1 Screening results.
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enabled comparison of the short-term responses of participants
whose initial screening results were not unequivocally normal/
negative. At T2, we distinguished screening outcome for partici-
pants with a positive baseline screening result who were free
from lung cancer (false-positive) from those who did have lung
cancer (true-positive) at long-term follow-up, those with normal
results (true-negative) and those with signiﬁcant abnormalities
during baseline or repeat CT scan that were not lung cancer
(incidental ﬁnding).
Statistical analysis
Analyses were conducted using SPSS (V.20; SPSS, Chicago,
Illinois, USA). Mean replacement imputation within domains
was used and a complete case analysis was carried out.
Individuals with missing data >35% within a domain were not
included in the analysis. Attrition bias was assessed using χ2 and
independent t tests. During primary analysis, psychosocial out-
comes of trial allocation and screening results at T1 and T2 were
assessed using analysis of covariance (ANCOVA) adjusted for T0
scores or χ2 tests. Due to non-normality and heterogeneity of
regression slopes for T1 cancer distress scores, analyses of trial
allocation effect on the primary outcome were conducted separ-
ately for log-transformed (logn) high and low cancer distress
thresholds, that is, above or below 12.5.24 Sensitivity analyses
were conducted to assess possible confounding effects of data
timing issues and to adjust for missing follow-up data at T1 and
T2 using an inverse probability weighting (IPW) approach.
27
The p values ≤0.01 were used to denote statistical signiﬁcance
in the context of multiple testing. Following signiﬁcant
ANCOVA results, post-hoc pairwise comparisons of screening
results were performed (p≤0.05).
A secondary linear mixed-effects risk prediction model was
generated to evaluate the impact of trial allocation on the
primary outcome of cancer distress at T1 and T2 in (1) uni-
variable regression analyses adjusting for T0 distress scores
and (2) multivariable regression analyses adjusting for T0
scores and all other main effects (gender, age group, smoking,
deprivation quintile, education, ethnicity, marital group, lung
cancer experience, trial site and time since attended recruit-
ment centre). The model ﬁtting process included mechanistic-
ally plausible confounders that exhibited independent
associations in a forward-stepping method using the likeli-
hood ratio statistic (p≤0.01), as part of an a priori statistical
analysis plan. Since only intervention group participants
received a CT scan, trial allocation group was fully nested
with the result group.
Figure 2 Trial ﬂow chart.
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RESULTS
Trial participation
In total, 4061 individuals (5.3% of 75 958 responders to the risk
questionnaire; 46.5% of all high-risk positive responders) attended
the recruitment clinic and were consented (see ﬁgure 2). Of these,
4037 trial participants completed T0 questionnaires and were ran-
domised (n=2018 intervention, n=2019 control), of whom 3232
completed T1 questionnaires (n=1653/84% intervention,
n=1579/78% control). At T2, 2855 participants completed ques-
tionnaires (n=1553/82% intervention, n=1302/65% control).
The mean time of T2 questionnaire completion was 16 months
after attending the recruitment centre (range 10–29 months).
Factors associated with study attrition
As shown in tables 1 and 2, intervention participants were statis-
tically signiﬁcantly more likely than those in the control arm to
complete T1 and T2. Questionnaire completers at T1 and T2
were signiﬁcantly more likely to be older, male, married or
cohabiting, more educated, former smokers, resident in the
Cambridge area and those who have had no experience of lung
cancer. Due to missing data for educational level, results for this
variable should be interpreted with caution. A signiﬁcantly
greater proportion of questionnaire completers were in the
highest IMD quintile at T1 and T2. T1 and T2 completers
reported signiﬁcantly lower baseline (T0) scores on all
Table 1 Attrition at short-term follow-up: comparison of T1 questionnaire completers and non-completers
T1 completers (n=3232)*
n (%) or mean (SD)
T1 non-completers (n=749)*
n (%) or mean (SD)
Test statistic
(p value)
Trial allocation
Intervention 1653 (51) 312 (42) <0.001
Control 1579 (49) 437 (58)
Site
Liverpool recruitment centre 1585 (49) 420 (56) <0.001
Cambridge recruitment centre 1647 (51) 329 (44)
Age (years) 67.73 (3.98) 67.28 (4.46) <0.01
Gender
Male 2446 (76) 533 (71) <0.01
Female 786 (24) 216 (29)
Education†
Up to GCSE/O level 1007 (43) 334 (57) <0.001
Beyond GCSE/O level 1310 (57) 250 (43)
Ethnicity
White 3190 (99) 739 (99) ‡
Non-white 26 (1) 10 (1)
Marital group
Married/cohabiting 2410 (75) 508 (68) <0.001
Not married/cohabiting 814 (25) 240 (32)
IMD
Quintile 1 (most deprived) 843 (26) 222 (30) <0.001
Quintile 2 367 (11) 109 (15)
Quintile 3 574 (18) 135 (18)
Quintile 4 578 (18) 141 (19)
Quintile 5 (least deprived) 870 (27) 142 (19)
Smoking status
Current smoker 1194 (37) 338 (45) <0.001
Ex-smoker 2037 (63) 410 (55)
Never smoker 1 (<1) 1 (<1) ‡
Experience of lung cancer (T0)
No 1870 (58) 396 (53) <0.01
Yes 1355 (42) 352 (47)
Cancer distress (T0)§ 2.16 (0.28)
8.65
2.21 (0.31)
9.16
<0.001
Anxiety (T0)§ 1.52 (0.71)
3.59
1.65 (0.71)
4.20
<0.001
Depression (T0)§ 1.27 (0.67)
2.56
1.37 (0.66)
2.94
<0.001
Decision satisfaction (T0)
Not very satisfied 1916 (59) 428 (57) 0.32
Very satisfied 1308 (41) 317 (43)
*Ns vary in each cell due to missing data. Percentages were calculated based on available data.
†A substantial amount of data were missing or uninformative for education.
‡Data were excluded from analysis due to limited variation.
§Logn scores are provided in normal text and original scale scores are provided in italics (analyses performed using logn scores).
GCSE, General Certificate of Secondary Education; IMD, Index of Multiple Deprivation.
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psychosocial measures, although the absolute differences were
very small and scores were in the low range overall. Differences
in decision satisfaction were not statistically signiﬁcant at either
follow-up.
Baseline sample characteristics
Most trial participants were male, white, married or cohabiting,
former smokers, with an average age of 68 years (see table 3).
Of those for whom educational data were available, just over
half the participants were educated beyond 16 years. There was
a spread of deprivation levels within the sample, with approxi-
mately one-quarter in the highest quintile and one-quarter in
the lowest quintile. T0 cancer distress, anxiety and depression
scores were equivalent across trial arms. Approximately 40%
were very satisﬁed with their decision to take part. The baseline
characteristics of participants who were included in T1 and T2
analyses are presented in additional online supplementary tables
SI and SII.
Primary analyses
Short-term (T1) outcomes
As shown in table 4, different effects of trial allocation on T1
cancer distress were found in participants who scored above and
below the T0 distress threshold (12.5). For those with low T0
Table 2 Attrition at long-term follow-up: comparison of T2 completers and non-completers
T2 completers (n=2855)*
n (%) or mean (SD)
T2 non-completers (n=1026)*
n (%) or mean (SD)
Test statistic
(p value)
Trial allocation
Intervention 1553 (54) 335 (33) <0.001
Control 1302 (46) 691 (67)
Site
Liverpool recruitment centre 1336 (47) 622 (61) <0.001
Cambridge recruitment centre 1519 (53) 404 (39)
Age (years) 67.79 (3.98) 67.19 (4.31) <0.001
Gender
Male 2166 (76) 736 (72) <0.01
Female 689 (24) 290 (28)
Education†
Up to GCSE/O level 940 (44) 367 (53) <0.001
Beyond GCSE/O level 1196 (56) 330 (47)
Ethnicity
White 2825 (99) 1004 (99) ‡
Non-white 21 (1) 15 (1)
Marital group
Married/cohabiting 2174 (76) 672 (66) <0.001
Not married/cohabiting 675 (24) 352 (34)
IMD
Quintile 1 (most deprived) 668 (23) 373 (36) <0.001
Quintile 2 338 (12) 126 (12)
Quintile 3 523 (18) 170 (17)
Quintile 4 545 (19) 157 (15)
Quintile 5 (least deprived) 781 (27) 200 (19)
Smoking status
Current smoker 1009 (35) 490 (48) <0.001
Ex-smoker 1845 (65) 536 (52)
Never smoker 1 (<1) 0 (0) ‡
Experience of lung cancer (T0)
No 1683 (59) 522 (51) <0.001
Yes 1166 (41) 503 (49)
Cancer distress (T0)§ 2.16 (0.28)
8.64
2.20 (0.32)
9.06
<0.001
Anxiety (T0)§ 1.51 (0.71)
3.52
1.64 (0.71)
4.17
<0.001
Depression (T0)§ 1.25 (0.66)
2.51
1.38 (0.68)
2.96
<0.001
Decision satisfaction (T0)
Not very satisfied 1668 (59) 612 (60) <0.47
Very satisfied 1179 (41) 410 (40)
*Ns vary in each cell due to missing data. Percentages were calculated based on available data.
†A substantial amount of data were missing or uninformative for education.
‡Data were excluded from analysis due to limited variation.
§Logn scores are provided in normal text and original scale scores are provided in italics (analyses performed using logn scores).
GCSE, General Certificate of Secondary Education; IMD, Index of Multiple Deprivation.
Brain K, et al. Thorax 2016;0:1–10. doi:10.1136/thoraxjnl-2016-208283 5
Lung cancer
group.bmj.com on January 6, 2017 - Published by http://thorax.bmj.com/Downloaded from 
distress (n=2896/3225, 90%), T1 distress scores were signiﬁ-
cantly higher in the intervention arm, though not to clinical
levels and with a very small effect size (logn (Int-Con)=0.03,
95% CI 0.02 to 0.05). For those with high T0 distress (n=326/
3225, 10%), the effect of trial allocation on T1 cancer distress
was not signiﬁcant: mean levels of cancer distress remained high
and bordered on clinical levels regardless of trial allocation
(153/326=47%) (logn (Int-Con)=−0.04, 95% CI −0.09 to
0.01).
The effect of trial allocation on T1 general anxiety was not
statistically signiﬁcant (logn (Int-Con)=−0.02, 95% CI −0.06 to
0.02). Higher logn depression scores were found in the control
group, but the absolute difference was very small (logn
(Int-Con)=−0.08, 95% CI −0.12 to −0.04). When converted
back to the original scale (0–21 range), depression scores were
within the normal range for both groups. At T1, a signiﬁcantly
greater proportion of control arm participants were not very sat-
isﬁed with their decision to take part (66%) compared with the
intervention arm (58%) (p≤0.001). Sensitivity analyses to assess
the impact of data timing showed no change in statistical signiﬁ-
cance levels; therefore, further exclusions were not made.
Further adjustment for missing data using IPW indicated no
change in the direction, magnitude or signiﬁcance of the differ-
ence in cancer distress between intervention and control arms
for either low or high scorers.
Intervention participants who were positive for MDT referral
at T1 reported statistically signiﬁcantly higher T1 cancer distress
which approached clinical thresholds (p≤0.001) compared with
those with negative results (p≤0.001), incidental ﬁndings
(p≤0.001) and those positive for a repeat scan (p≤0.001).
Participants who required a repeat scan at T1 reported signiﬁ-
cantly higher T1 cancer distress than those with negative results
(p≤0.001). Statistically signiﬁcantly greater anxiety was found
in participants referred to MDT (p≤0.001) compared with
those receiving negative results (p≤0.001), incidental ﬁndings
(p=0.02) or positive for repeat scan (p=0.003), although
scores were in the low/normal range. The difference in anxiety
between those positive for MDTreferral and those with inciden-
tal ﬁndings disappeared when sensitivity analysis accounted for
test timing issues. Differences in depression scores were not stat-
istically signiﬁcant for any screening result group (p=0.35).
Intervention participants who were positive for a repeat scan
were the least satisﬁed with their decision (p≤0.001).
Long-term (T2) outcomes
The effect of trial allocation on T2 cancer distress was not statis-
tically signiﬁcant in individuals with low (logn (Int-Con)=0.01,
95% CI −0.01 to 0.02) or high (logn (Int-Con)=−0.02, 95% CI
−0.09 to 0.05) T0 distress (see table 5). Although the control
group reported signiﬁcantly higher T2 logn anxiety (logn
(Int-Con)=−0.08, 95% CI −0.12 to −0.03) and depression
(logn (Int-Con)=−0.06, 95% CI −0.10 to −0.02), the absolute
differences between trial arms were small and not clinically sig-
niﬁcant. When converted to raw scores, all three measures for
both trial arms were within the normal range. Control partici-
pants (74%) were signiﬁcantly less likely than intervention parti-
cipants (60%) to be very satisﬁed with their decision to take
part (p≤0.001).
Differences between screening outcome groups in T2 cancer
distress (p=0.04), anxiety (p=0.12), depression (p=0.11) and
decision satisfaction (p=0.03) were not statistically signiﬁcant.
The raw scores of all psychosocial variables in all screening
outcome groups were within the normal range and not clinically
relevant. Sensitivity analyses using IPW to assess the impact of
missing data indicated no change in the direction, magnitude or
signiﬁcance of the difference in cancer distress between inter-
vention and control arms, either for low or high baseline
scorers.
Secondary analyses
In univariable analyses, the mean difference in logn cancer dis-
tress scores between the intervention and control arms was not
statistically signiﬁcant after adjustment for T0 cancer distress
and independent effect modiﬁers (see table 6). This equated to
a relative increase of 2% for intervention arm participants when
Table 3 Baseline psychosocial sample characteristics by trial
allocation
Intervention
(n=2018)*
n (%) or mean (SD)
Control (n=2019)*
n (%) or mean (SD)
Site
Liverpool recruitment centre 1003 (50) 1016 (50)
Cambridgeshire recruitment
centre
1002 (50) 1016 (50)
Age (years) 67.72 (4.04) 67.59 (4.13)
Gender
Male 1520 (75) 1500 (74)
Female 498 (25) 519 (26)
Education†
Up to GCSE/O level or
equivalent
678 (46) 683 (46)
Beyond GCSE/O level or
equivalent
788 (54) 791 (54)
Ethnicity
White 1992 (99) 1992 (99)
Non-white 18 (1) 19 (1)
Marital group
Married/cohabiting 1483 (74) 1471 (73)
Not married/cohabiting 528 (26) 545 (27)
IMD
Quintile 1 (most deprived) 545 (27) 533 (26)
Quintile 2 243 (12) 242 (12)
Quintile 3 358 (18) 361 (18)
Quintile 4 353 (18) 376 (19)
Quintile 5 (least deprived) 519 (26) 507 (25)
Smoking status
Current smoker 772 (38) 787 (39)
Ex-smoker 1244 (62) 1232 (61)
Never smoker 2 (<1) 0 (0)
Experience of lung cancer (T0)
No 1168 (58) 1126 (56)
Yes 846 (42) 889 (44)
Cancer distress (T0)‡ 2.17 (0.29)
8.75
2.17 (0.29)
8.74
Anxiety (T0)‡ 1.55 (0.71)
3.72
1.54 (0.71)
3.67
Depression (T0)‡ 1.30 (0.68)
2.66
1.28 (0.67)
2.61
Decision satisfaction (T0)
Not very satisfied 1228 (61) 1158 (58)
Very satisfied 786 (39) 853 (42)
*Ns vary in each cell due to missing data. Percentages were calculated based on
available data.
†A substantial amount of data were missing or uninformative for education.
‡Logn scores are provided in normal text and original scale scores are provided in
italics (analyses performed using logn scores).
GCSE, General Certificate of Secondary Education; IMD, Index of Multiple Deprivation.
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distress scores were back-transformed (95% CI 12% to 17%).
Cancer distress scores were statistically signiﬁcantly higher in
women (p≤0.001), younger participants (≤65 years and 66–
70 years) compared with those aged over 70 (p≤0.001), current
smokers compared with ex-smokers (p≤0.001), lower socio-
economic groups (Q1-Q2 vs Q5 p≤0.001, Q3 vs Q5 p≤0.01),
single or divorced compared with married individuals
(p≤0.001), those with experience of lung cancer (p≤0.001) and
participants recruited from the Liverpool area (p≤0.001).
Education, ethnicity and time since recruitment were not signiﬁ-
cantly independently associated with cancer distress.
Intervention participants who needed a repeat scan or MDT
referral reported higher cancer distress than those who received
a negative result (p≤0.001).
In multivariable analyses adjusting for covariates, the impact
of trial allocation on cancer distress was not statistically signiﬁ-
cant. Higher cancer distress was statistically signiﬁcantly asso-
ciated with female gender (p≤0.01), younger age group (≤65 vs
over 70 years) (p≤0.001), current smoking status (p≤0.001),
lung cancer experience (p≤0.001) and Liverpool recruitment
site (p≤0.001).
Sensitivity analyses to assess the impact of T0 cancer distress
level indicated a similar pattern of results for participants with
high T0 cancer distress levels.
Table 4 Summary data for short-term psychosocial outcomes (T1) by trial arm and screening result
Outcome (T1)
Intervention
(n=1653)
Control
(n=1579)
Intervention arm (n=1653) by screening result†
Negative
(n=763)
Incidental finding
(n=41)
Positive—repeat scan
(n=788)
Positive—MDT referral
(n=48)
Cancer distress‡
M (95% CI)
Low T0 scorers
2.14 (2.13 to 2.16)**
8.54 (8.44 to 8.64)
Low T0 scorers
2.11 (2.10 to 2.12)
8.26 (8.16 to 8.36)
2.12 (2.10 to 2.13)
8.32 (8.18 to 8.45)
2.15 (2.08 to 2.22)
8.56 (7.97 to 9.19)
2.23 (2.22 to 2.25)**
9.34 (9.19 to 9.49)
2.47 (2.41 to 2.54)**
11.88 (11.10 to 12.72)
High T0 scorers
2.50 (2.46 to 2.53)
12.14 (11.73 to 12.55)
High T0 scorers
2.53 (2.50 to 2.57)
12.61 (12.15 to 13.09)
Anxiety‡
M (95% CI) 1.54 (1.51 to 1.57)
3.67 (3.54 to 3.80)
1.56 (1.53 to 1.59)
3.78 (3.64 to 3.92)
1.51 (1.47 to 1.55)
3.54 (3.35 to 3.73)
1.50 (1.32 to 1.68)
3.49 (2.75 to 4.39)
1.56 (1.52 to 1.60)
3.76 (3.57 to 3.96)
1.87 (1.70 to 2.04)**
5.49 (4.48 to 6.67)
Depression‡
M (95% CI) 1.26 (1.23 to 1.29)
2.53 (2.42 to 2.63)
1.34 (1.31 to 1.37)**
2.81 (2.70 to 2.92)
1.27 (1.23 to 1.31)
2.55 (2.41 to 2.70)
1.20 (1.02 to 1.38)
2.31 (1.76 to 2.97)
1.26 (1.22 to 1.30)
2.51 (2.37 to 2.66)
1.40 (1.24 to 1.56)
3.05 (2.44 to 3.78)
Decision satisfaction (n, %)
Not very satisfied
Very satisfied
875 (58)
624 (42)
953 (66)**
498 (34)
378 (54)
324 (46)
22 (56)
17 (44)
450 (64)**
255 (36)
18 (43)
24 (57)
*p≤0.01, **p≤0.001.
Numbers vary in each cell due to missing data.
†n=13 excluded at T1 due to discrepancies in the classification of baseline CT scan results.
‡Logn scores are provided in normal text and original scale scores are provided in italics (analyses performed using logn scores). Estimated marginal means are presented. Higher scores
denote higher levels of the relevant outcome.
Table 5 Summary data for long-term psychosocial outcomes (T2) by trial arm and screening outcome
Outcome (T2)
Intervention
(n=1553)
Control
(n=1302)
Intervention arm (n=1553) by screening outcome†
True-negative
(n=740)
Incidental finding
(n=78)
False-positive
(n=445)
True-positive
(n=23)
Cancer distress‡
M (95% CI)
Low T0 scorers
2.10 (2.09 to 2.11)
8.15 (8.05 to 8.25)
Low T0 scorers
2.09 (2.08 to 2.10)
8.10 (7.99 to 8.25)
2.11 (2.09 to 2.12)
8.22 (8.09 to 8.36)
2.14 (2.09 to 2.19)
8.48 (8.06 to 8.93)
2.14 (2.12 to 2.16)
8.51 (8.33 to 8.70)
2.20 (2.10 to 2.30)
9.01 (8.16 to 9.96)
High T0 scorers
2.44 (2.39 to 2.48)
11.43 (10.93 to 11.95)
High T0 scorers
2.46 (2.41 to 2.51)
11.69 (11.11 to 12.30)
Anxiety‡
M (95% CI) 1.54 (1.51 to 1.57)
3.66 (3.52 to 3.80)
1.61 (1.58 to 1.65)**
4.02 (3.86 to 4.19)
1.57 (1.53 to 1.62)
3.82 (3.61 to 4.03)
1.45 (1.32 to 1.59)
3.28 (2.74 to 3.89)
1.52 (1.47 to 1.58)
3.59 (3.34 to 3.85)
1.37 (1.13 to 1.62)
2.94 (2.08 to 4.03)
Depression‡
M (95% CI) 1.33 (1.30 to 1.36)
2.77 (2.67 to 2.89)
1.39 (1.36 to 1.42)*
3.01 (2.89 to 3.14)
1.34 (1.30 to 1.39)
2.84 (2.68 to 3.00)
1.22 (1.09 to 1.35)
2.38 (1.97 to 2.85)
1.38 (1.33 to 1.44)
2.98 (2.78 to 3.20)
1.26 (1.02 to 1.49)
2.52 (1.79 to 3.44)
Decision satisfaction (n, %)
Not very satisfied
Very satisfied
855 (60)
567 (40)
883 (74)**
306 (26)
411 (61)
267 (39)
39 (55)
32 (45)
239 (59)
169 (41)
6 (29)§
15 (71)
*p≤0.01, **p≤0.001.
Ns vary in each cell due to missing data.
†n=267 were excluded at T2 if they had no baseline scan, had a MDT referral but no lung cancer diagnosed, were awaiting scan or results, or had results that were not classified.
‡Logn scores are provided in normal text and original scale scores are provided in italics (analyses performed using logn scores). Estimated marginal means are presented. Higher scores
denote higher levels of the relevant outcome.
§Test statistics not calculated due to low variation.
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DISCUSSION
The present study is the ﬁrst to report the long-term psycho-
social impact of LDCT screening in a UK high-risk population.
Transient negative consequences were observed in individuals
allocated to LDCT screening and in those who received
unfavourable screening results, but these differences were
neither sustained over time nor clinically signiﬁcant. However, a
proﬁle of risk factors emerged for adverse consequences of par-
ticipating in lung cancer screening.
The overall ﬁndings conﬁrm evidence from non-UK con-
trolled trials that allocation to LDCT screening does not appear
to produce long-term anxiety or other adverse effects that could
potentially deter high-risk individuals from future adherence to
lung screening. In studies with repeated screening such as NLST,
the majority of participants returned for further screenings.4
NELSON8 and PLCO9 observed minimal long-term psycho-
social effects of LDCT screening. Although UKLS participants
who were assigned to the control group reported slightly higher
long-term anxiety and depression, the absolute differences were
very small and not clinically signiﬁcant. This ﬁnding may reﬂect
unscreened participants’ disappointment or frustration at having
been identiﬁed as high risk but denied the opportunity to gain
reassurance from screening, supported by the ﬁnding that a
greater proportion were less satisﬁed with their decision to par-
ticipate compared with the intervention arm. Similarly, the
DLCST reported negative consequences in the unscreened
control arm at 16 and 2 years.7
The short-term impact of UKLS participation largely reﬂected
temporary adverse effects of positive screening results, which
disappeared by 2 years follow-up. This ﬁnding supports previ-
ous LDCT trials that indicate long-term resolution of adverse
screening effects.8 9 11 Unsurprisingly, participants who were
referred due to a suspected major lung abnormality reported
higher short-term cancer distress than any other screening result
group, with levels close to threshold scores. Those who required
a repeat scan reported higher distress than those receiving an
immediate ‘all-clear’ result. Higher short-term anxiety was
observed in participants with a suspected major lung abnormal-
ity, but scores were within the normal range and they were also
more at ease with their decision to take part in the trial. The
latter ﬁnding has been reported in other screening evaluation
studies, suggesting decision consolidation and the perception
that further diagnostic tests have been carried out thoroughly
and for personal beneﬁt.28
Table 6 Univariable and multivariable analyses of trial allocation effects on cancer distress over T1 and T2
Cancer distress effect modifiers
Logn difference in cancer distress
Estimate (unadjusted), 95% CI, p value Estimate (adjusted)*, 95% CI, p value
Trial allocation (Intervention–Control) 0.02 (−0.13 to 0.17) 0.42 0.03 (−0.20 to 0.26) 0.39
Gender (Female–Male) 0.04 (0.03 to 0.06) ≤0.001 0.02 (0.01 to 0.04) ≤0.01
Age group
Up to 65–over 70 0.06 (0.05 to 0.08) ≤0.001 0.05 (0.03 to 0.07) ≤0.001
66 to 70–over 70 0.04 (0.02 to 0.05) ≤0.001 0.02 (0.02 to 0.04) 0.02
Smoking
Ex-smoker–Current smoker −0.08 (−0.06 to −0.09) ≤0.001 −0.06 (−0.05 to −0.08) ≤0.001
Never smoker†–Current smoker † †
IMD
Q1 (most deprived)–Q5 (least deprived) 0.09 (0.07 to 0.10) ≤0.001 0.02 (−0.01 to 0.04) 0.13
Q2–Q5 0.05 (0.03 to 0.07) ≤0.001 0.01 (−0.02 to 0.03) 0.66
Q3–Q5 0.03 (0.01 to 0.04) ≤0.01 −0.00 (−0.02 to 0.02) 0.89
Q4–Q5 0.02 (0.00 to 0.04) 0.029 0.01 (−0.01 to 0.03) 0.59
Education (Up to GCSE/O level–beyond GCSE/O level) 0.01 (0.00 to 0.03) 0.05 –
Ethnicity (White–non-white) 0.01 (−0.06 to 0.08) 0.79 –
Marital group
Married–Single −0.04 (−0.02 to –0.07) ≤0.001 –
Married–Cohabiting 0.01 (−0.02 to 0.04) 0.41 –
Married–Widowed −0.03 (−0.00 to –0.05) 0.03 –
Married–Divorced −0.05 (−0.03 to –0.07) ≤0.001 –
Experience of lung cancer (Yes–No) 0.05 (0.03 to 0.06) ≤0.001 0.03 (0.02 to 0.05) ≤0.001
Site (Liverpool–Cambridge) 0.07 (0.06 to 0.08) ≤0.001 0.06 (0.04 to 0.07) ≤0.001
Time since attended recruitment centre
3 to 6 months–<3 months −0.00 (−0.03 to 0.03) 1.00 −0.03 (0.00 to −0.05) 0.09
6 to 12 months–<3 months −0.05 (−0.09 to −0.01) 0.03 −0.06 (−0.11 to −0.01) 0.03
>12 months–<3 months −0.03 (−0.12 to 0.06) 0.09 −0.05 (−0.00 to −0.10) 0.05
Screening result
Positive (repeat scan)–Negative 0.09 (0.07 to 0.11) ≤0.001 –
Positive (referral)–Negative 0.20 (0.15 to 0.24) ≤0.001 –
Incidental–Negative 0.02 (−0.02 to 0.07) 0.33 –
Data are presented for participants with low T0 cancer distress (n=2896/3225, 90%). Base model adjustment factors included: T0 cancer distress, trial allocation, gender, age, smoking,
deprivation, education, ethnicity, marital group, time since recruitment, recruitment site and experience of lung cancer.
*Adjusted for T0 cancer distress, trial allocation, gender, age, smoking, deprivation, time since recruitment, recruitment site and experience of lung cancer.
†Data were excluded due to limited variation.
GCSE, General Certificate of Secondary Education; IMD, Index of Multiple Deprivation.
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Individual difference variables that predicted higher levels of
cancer distress over time, irrespective of trial allocation,
included female gender and younger age (under 65 years).
Women may feel more worried and less prepared for the pros-
pect of lung cancer screening than men, possibly due to expos-
ure to female cancer screening programmes and perceptions of
lung cancer as a traditionally male disease. Smokers and those
who had been exposed to lung cancer in their social networks
were also more concerned about lung cancer. Perceived stigma
and fatalism surrounding a lung cancer diagnosis are important
issues, especially for smokers.14 16 17 This may be partly due to
adverse vicarious experiences (ie, witnessing poor outcomes in
family and friends with lung cancer) that inﬂuence the forma-
tion of negative beliefs and attitudes towards lung cancer screen-
ing. The links between smoking, socioeconomic deprivation and
lung cancer incidence and mortality are well known29 30 and
psychosocial outcomes were indeed poorer in those recruited
from the Liverpool area, which is known to have high levels of
deprivation and high incidence of lung cancer.31 Supportive
interventions to improve the quality of information and care
and minimise potential distress in vulnerable groups, should be
implemented alongside routine LDCT lung screening. In add-
ition, individuals with high pre-existing cancer distress could be
identiﬁed for psychosocial support.24
While the overall trend towards minimal psychosocial conse-
quences of UKLS is encouraging, we acknowledge the possibility
that sample selection bias may limit external validity. High-risk
individuals who were older, female, smokers, from a lower
socioeconomic group or more concerned about lung cancer
were less likely to participate21 and continued to be under-
represented as the trial progressed. These ﬁndings are consistent
with barriers to uptake that have been reported in previous lung
screening trials.14 16 17 32 The current ﬁndings suggest that
women may initially be less aware or convinced of the need for
lung screening, compared with breast and cervical cancers
where there are well-established screening programmes. In the
DLCST, trial participation was similarly associated with depriv-
ation and age, but in contrast to our ﬁndings men were under-
represented in the DLCST.33 Further in-depth qualitative
research is required to understand the perceptions and attitudes
of men and women who are at high risk and eligible for lung
cancer screening.
We also recognise that sample bias may have led to potential
type II error in detecting long-term effects of LDCT screening,
due to the relatively small number of participants with true-
positive or signiﬁcant incidental results. Gareen et al12
reported poorer health-related quality of life and higher state
anxiety in NLST participants who received a lung cancer diag-
nosis. Some participants were excluded from screening out-
comes analyses, for example, those referred but in whom lung
cancer was not diagnosed. Long-term psychosocial effects in
these individuals are unknown. Interestingly, there was no
observed difference in distress between participants who had
incidental non-lung cancer ﬁndings compared with those with
negative results. However, the number of signiﬁcant incidental
ﬁndings may increase in routine practice compared with a trial
setting. The potential for distress caused by unfavourable or
unexpected ﬁndings of lung screening should not be ruled out.
We acknowledge that, in future, the psychosocial consequences
of lung cancer screening will need to be examined in the
context of a health service (if implemented) and that the
single-screen design of the UKLS trial may limit the generalis-
ability of our ﬁndings to the context of enrolment in a routine
screening programme.
LDCT lung screening is currently recommended in the US,
but policy decisions in Europe await pooled data from
European trials.34 There is an ethical imperative to promote
informed participation in lung cancer screening prior to its
routine implementation in the UK. Public and patient facing
information materials should aim to prepare people for
informed participation by increasing understanding of the
purpose, beneﬁts and risks of lung screening, including the pos-
sibility of receiving abnormal results and strategies for coping
with associated short-term distress. Interventions that target
smokers may improve informed participation in lung screening
and provide a platform from which to engage smokers in
smoking cessation services.
The present results must be interpreted alongside evidence of
feasibility, cost-effectiveness and reach to determine whether
LDCT lung cancer screening should become programmatic in the
UK. Strategies for engaging and supporting high risk, harder to
reach groups should also be trialled if lung cancer screening is to
be successfully and equitably rolled out in the community setting.
Twitter Follow Kate Brain at @Katebrain
Acknowledgements The authors wish to thank Bev Green for her invaluable
contribution to trial administration, Ghasem Yadegarfar for assisting with trial data
collection and the trial participants who gave their time in completing
questionnaires. They also thank the anonymous reviewers for their helpful
comments.
Contributors KB: Trial conception and design, data analysis, data interpretation
and manuscript preparation. KJL: Data collection, data analysis, data interpretation
and manuscript review. BC: Trial statistician and manuscript review. OB: Data
analysis and interpretation and manuscript review. FM: Data collection and
manuscript review. AD: Radiological review, data interpretation and manuscript
review. DMH: Trial design, radiological review, data interpretation and manuscript
review. DB: Trial design, UK Lung Cancer Screening (UKLS) care pathway, data
interpretation and manuscript review. SWD: Trial design, statistical analysis, data
interpretation and manuscript review. JKF: Trial conception and design, data
interpretation and manuscript review.
Funding National Institute for Health Research Health Technology Assessment
programme, grant reference no. HTA 09/61/01.
Competing interests None declared.
Patient consent Obtained.
Ethics approval Ethical approval for the study was given by Liverpool Central
Research Ethics Committee in December 2010 (reference number 10/H1005/74). All
UKLS participants provided informed consent before taking part. The trial was
registered with the International Standard Randomised Controlled Trial Register
(ISRCTN) under the reference 78513845.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/
by/4.0/
REFERENCES
1 Cancer Research UK. Lung cancer statistics. http://www.cancerresearchuk.org/
health-professional/cancer-statistics/statistics-by-cancer-type/
lung-cancer#heading-One (accessed 13 Nov 2015).
2 Walters S, Benitez-Majano S, Muller P, et al. Is England closing the international
gap in cancer survival? Brit J Cancer 2015;113:848–60.
3 Lyratzopoulos G, Abel GA, Brown CH, et al. Socio-demographic inequalities in stage
of cancer diagnosis: evidence from patients with female breast, lung, colon, rectal,
prostate, renal, bladder, melanoma, ovarian and endometrial cancer. Ann Oncol
2013;24:843–50.
4 Aberle DR, Adams AM, Berg CD, et al., National Lung Screening Trial Research
Team. Reduced lung-cancer mortality with low-dose computed tomographic
screening. N Engl J Med 2011;365:395–409.
5 O’Connor GT, Hatabu H. Lung cancer screening, radiation, risks, beneﬁts, and
uncertainty. JAMA 2012;307:2434–5.
6 Aggestrup LM, Hestbech MS, Siersma V, et al. Psychosocial consequences of
allocation to lung cancer screening: a randomised controlled trial. BMJ Open
2012;2:e000663.
Brain K, et al. Thorax 2016;0:1–10. doi:10.1136/thoraxjnl-2016-208283 9
Lung cancer
group.bmj.com on January 6, 2017 - Published by http://thorax.bmj.com/Downloaded from 
7 Rasmussen JF, Siersma V, Pedersen JH, et al. Psychosocial consequences in the
Danish randomised controlled lung cancer screening trial (DLCST). Lung Cancer
2015;87:65–72.
8 van den Bergh KAM, Essink-Bot ML, Borsboom GJJM, et al. Long-term effects of
lung cancer computed tomography screening on health-related quality of life: the
NELSON trial. Eur Respir J 2011;38:154–61.
9 Taylor KL, Shelby R, Gelmann E, et al. Quality of life and trial adherence among
participants in the prostate, lung, colorectal, and ovarian cancer screening trial.
J Natl Cancer Inst 2004;96:1083–94.
10 Byrne MM, Weissfeld J, Roberts MS. Anxiety, fear of cancer, and perceived risk of
cancer following lung cancer screening. Med Decis Making 2008;28:917–25.
11 van den Bergh KAM, Essink-Bot ML, Borsboom GJJM, et al. Short-term
health-related quality of life consequences in a lung cancer CT screening trial
(NELSON). Br J Cancer 2010;102:27–34.
12 Gareen IF, Duan F, Greco EM, et al. Impact of lung cancer screening results on
participant health-related quality of life and state anxiety in the National Lung
Screening Trial. Cancer 2014;120:3401–9.
13 Field JK, Duffy SW, Baldwin DR, et al. UK Lung Cancer RCT Pilot Screening Trial:
baseline ﬁndings from the screening arm provide evidence for the potential
implementation of lung cancer screening. Thorax 2016;71:161–70.
14 Silvestri GA, Nietert PJ, Zoller J, et al. Attitudes towards screening for lung cancer
among smokers and their non-smoking counterparts. Thorax 2007;62:126–30.
15 van den Bergh KAM, Essink-Bot ML, van Klaveren RJ, et al. Informed participation
in a randomised controlled trial of computed tomography screening for lung cancer.
Eur Respir J 2009;34:711–20.
16 Patel D, Akporobaro A, Chinyanganya N, et al. Attitudes to participation in a lung
cancer screening trial: a qualitative study. Thorax 2012;67:418–25.
17 Jonnalagadda S, Bergamo C, Lin JJ, et al. Beliefs and attitudes about lung cancer
screening among smokers. Lung Cancer 2012;77:526–31.
18 Quaife SL, McEwen A, Janes SM, et al. Smoking is associated with pessimistic and
avoidant beliefs about cancer: results from the International Cancer Benchmarking
Partnership. Brit J Cancer 2015;112:1799–804.
19 von Wagner C, Baio G, Raine R, et al. Inequalities in participation in an organized
national colorectal cancer screening programme: results from the ﬁrst 2.6 million
invitations in England. Int J Epid 2011;40:712–18.
20 McRonald FE, Yadegarfar G, Baldwin DR, et al. The UK Lung Screen (UKLS):
demographic proﬁle of ﬁrst 88,897 approaches provides recommendations for
population screening. Cancer Prev Res 2014;7:362–71.
21 Ali N, Lifford KJ, Carter B, et al. Barriers to uptake among high-risk individuals
declining participation in lung cancer screening: a mixed-methods analysis of the
United Kingdom Lung Cancer Screening (UKLS) trial. BMJ Open 2015; 5:
e008254.
22 Lerman C, Daly M, Sands C. Mammography adherence and psychological distress
among women at risk for breast cancer. J Natl Cancer Inst 1993;85:1074–80.
23 Watson M, Lloyd S, Davidson J, et al. The impact of genetic counselling on risk
perception and mental health in women with a family history of breast cancer. Brit J
Cancer 1999;79:868–74.
24 Brain K, Parsons E, Bennett P, et al. The evolution of worry after breast cancer risk
assessment: 6-year follow-up of the TRACE study cohort. Psycho-Oncol
2011;20:984–91.
25 Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr
Scand 1983;67:361–70.
26 Holmes-Rovner M, Kroll J, Schmitt N, et al. Patient satisfaction with health care
decisions: the satisfaction with decision scale. Med Decis Making 1996;
16:58–64.
27 Seaman SR, White IR. Review of inverse probability weighting for dealing with
missing data. Stat Methods Med Res 2013;22:278–95.
28 Clements A, Henderson BJ, Tyndel S, et al. Diagnosed with breast cancer while on
a family history screening programme: an exploratory qualitative study. Eur J Cancer
Care 2008;17:245–52.
29 Cancer Research UK. Tobacco statistics. http://www.cancerresearchuk.org/
health-professional/cancer-statistics/risk/tobacco#heading-One (accessed 13 Nov
2015).
30 Ofﬁce for National Statistics. Do smoking rates vary between more and less advantaged
areas? http://www.ons.gov.uk/ons/rel/disability-and-health-measurement/do-smoking
-rates-vary-between-more-and-less-advantaged-areas-/2012/index.html (accessed 13
Nov 2015).
31 Shack L, Jordan C, Thomson CS, et al. Variation in incidence of breast, lung and
cervical cancer and malignant melanoma of skin by socioeconomic group in
England. BMC Cancer 2008;8:271.
32 Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-,
sex-, and age-based disparities. JAMA 2004;291:2720–6.
33 Hestbech MS, Siersma V, Dirksen A, et al. Participation bias in a randomised trial of
screening for lung cancer. Lung Cancer 2011;73:325–31.
34 Field JK, van Klaveren R, Pedersen JH, et al. European randomized lung cancer
screening trials: post NLST. J Surg Oncol 2013;108:280–6.
10 Brain K, et al. Thorax 2016;0:1–10. doi:10.1136/thoraxjnl-2016-208283
Lung cancer
group.bmj.com on January 6, 2017 - Published by http://thorax.bmj.com/Downloaded from 
controlled trial
Lung Cancer Screening randomised
low-dose CT screening: results of the UK 
Long-term psychosocial outcomes of
John K Field
Anand Devaraj, David M Hansell, David Baldwin, Stephen W Duffy and 
Kate Brain, Kate J Lifford, Ben Carter, Olivia Burke, Fiona McRonald,
 published online July 28, 2016Thorax 
 3
http://thorax.bmj.com/content/early/2016/07/27/thoraxjnl-2016-20828
Updated information and services can be found at: 
These include:
References
 #BIBL3
http://thorax.bmj.com/content/early/2016/07/27/thoraxjnl-2016-20828
This article cites 31 articles, 15 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (1039)Tobacco use
 (1037)Smoking
 (1223)Health education
 (339)General practice / family medicine
 (557)Clinical trials (epidemiology)
 (211)Health effects of tobacco use
 (608)Lung neoplasms
 (670)Lung cancer (respiratory medicine)
 (670)Lung cancer (oncology)
 (407)Screening (oncology)
 (366)Screening (public health)
 (366)Screening (epidemiology)
 (230)Open access
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on January 6, 2017 - Published by http://thorax.bmj.com/Downloaded from 
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on January 6, 2017 - Published by http://thorax.bmj.com/Downloaded from 
